Clinical trials
Focal Segmental Glomerulosclerosis (FSGS) clinical trials
Below are recruiting focal segmental glomerulosclerosis (fsgs) clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02235857Recruiting
Device treatment study for children with focal segmental kidney scarring
This trial studies a medical device (the Liposorber LA-15) in children with focal segmental glomerulosclerosis (FSGS), a kidney condition that can cause heavy protein loss in the urine. It may help by improving disease control when standard treatments have not worked, were hard to tolerate, or can’t be used.
Loma Linda, CaliforniaAges Up to 21 years - NCT07220083RecruitingPhase 3
A study of BI 764198 for people with FSGS kidney disease
This trial tests if a new medicine called BI 764198 can help people with a kidney condition called FSGS. It looks at whether the drug can reduce protein in the urine and protect kidney function.
Alabaster, AlabamaAges 12 years+ - NCT07268638RecruitingPhase 2
Study of praliciguat for focal segmental glomerulosclerosis
This trial tests an investigational drug called praliciguat for people with FSGS, a kidney disease that causes scarring in the kidney filters. The goal is to see if praliciguat can help reduce protein in the urine and protect kidney function.
Chula Vista, CaliforniaAges 18 years+ - NCT07614477RecruitingPhase 2
Testing EVER001 for kidney protein-loss diseases
This study tests a new drug called EVER001 to see if it can reduce protein loss in urine and improve kidney function in patients with specific kidney diseases (FSGS, MCD, or IgAN). These are autoimmune kidney conditions that cause the kidneys to leak protein into the urine.
Beijing, Beijing MunicipalityAges 18–75 - NCT06500702RecruitingPhase 2
Study of three drugs for FSGS or minimal change disease
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
Birmingham, AlabamaAges 16–75 - NCT03949972Recruiting
FSGS and MCD patient registry for kidney disease
This study is a registry that collects medical information from people with nephrotic syndrome caused by FSGS or minimal change disease (MCD). It may help doctors better understand these conditions and improve future care, especially by tracking patients over time.
Cologne, North Rhine-WestphaliaAges Any age - NCT05650619Recruiting
Study of return of kidney disease after transplant
This observational study looks at people with FSGS or minimal change disease whose kidney disease came back after a transplant. The goal is to better understand patterns of recurrence and what factors may be linked to it.
Ann Arbor, MichiganAges Any age - NCT06090227RecruitingPhase 1/Phase 2
Metformin for FSGS: A phase 1/2 trial
This trial tests whether the diabetes drug metformin can help people with a kidney disease called FSGS, by activating a cell-protecting pathway. Participants will take metformin or a placebo along with their usual steroid treatment.
New Haven, ConnecticutAges 18–80 - NCT06760845Recruiting
Using light to diagnose kidney disease
This trial uses a special light technique (Raman spectroscopy) to help diagnose different types of kidney disease. It may provide a faster, less invasive way to understand your condition.
Jinan, ShandongAges Any age - NCT07499700RecruitingPhase 2/Phase 3
Study of BAT4406F injection for MCD and FSGS
This trial tests an injected drug called BAT4406F for people with Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS), two types of kidney diseases that cause swelling and high protein in urine. It aims to see if the drug can help patients who have responded well to steroid therapy in the past.
Beijing, Beijing MunicipalityAges 18–75 - NCT07516964Recruiting
Studying autoimmune kidney disease in children and adults
This study collects medical information and samples from patients with podocytopathy—a type of autoimmune kidney disease that causes protein leakage into urine. Researchers will analyze your medical records and any blood or kidney tissue samples you've already had to better understand the disease and find better treatments.
Rochester, MinnesotaAges birth–99 years - NCT04065438Recruiting
Study of a blood-filter treatment for FSGS not responding to meds
This study looks at how well a specialized blood-filter device (the LIPOSORBER® LA-15) works for people with primary FSGS—especially when standard steroid and other medicines don’t work or can’t be tolerated. It may help reduce disease activity, particularly in people with kidney function that is still moderate or in those after kidney transplant.
Loma Linda, CaliforniaAges Up to 75 years - NCT04571658Recruiting
NEPTUNE Match study linking you to possible kidney research trials
This study is an add-on process that uses information from the NEPTUNE kidney study to see whether you might be able to join other kidney research trials. It may help connect eligible people with appropriate new treatment studies when they become available.
Atlanta, GeorgiaAges 1–80 - NCT06664814RecruitingPhase 2
Study of ManNAc for kidney diseases with proteinuria
This study tests a new drug called ManNAc for people with certain kidney diseases (FSGS, MCD, or MN) that cause protein in the urine. The goal is to see if this drug can help reduce protein loss and improve kidney health.
Bethesda, MarylandAges 18–115 - NCT05003986RecruitingPhase 2
Sparsentan for children with protein leaking kidney diseases
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
Los Angeles, CaliforniaAges 1–17 - NCT05505500Recruiting
Parent and patient interviews for childhood kidney swelling
This study uses interviews to understand how swelling from nephrotic syndrome affects daily life for children and their caregivers. It may help researchers design better care by capturing the patient and parent perspective.
Ann Arbor, MichiganAges 2 years+ - NCT05583942Recruiting
Nerve stimulation trial for children with steroid-resistant kidney syndrome
This pilot study tests a device that stimulates nerves in the ear to help children with steroid-resistant nephrotic syndrome. It may improve urine protein and kidney-related outcomes for kids whose standard steroid treatment does not work.
New Hyde Park, New YorkAges 3–17 - NCT05588063Recruiting
Device-based nerve stimulation for relapse-preventing kidney disease in kids
This trial tests whether a small non-surgical device can help keep children with steroid-sensitive nephrotic syndrome in remission. If it works, it could lower the chance of relapse (kidney flare-ups) and help maintain kidney health.
New Hyde Park, New YorkAges 3–17
Hear when a new Focal Segmental Glomerulosclerosis (FSGS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for focal segmental glomerulosclerosis (fsgs)?
- Yes. Clin2 currently lists 18 recruiting focal segmental glomerulosclerosis (fsgs) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a focal segmental glomerulosclerosis (fsgs) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a focal segmental glomerulosclerosis (fsgs) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.